cetrorelix: Clinical Trials

13 trials of cetrorelix, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 3 unknown, 1 not yet recruiting, 1 terminated. 13 Phase 2, 4 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 213Completed 7, Unknown 3, Not yet recruiting 1, Terminated 1, Withdrawn 1
Phase 14Completed 2, Not yet recruiting 1, Withdrawn 1
Phase 32Completed 1, Unknown 1

Follow cetrorelix: new trials by email Literature Review of cetrorelix trials Research Report on cetrorelix

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Drospirenone-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing Freeze-All IVF/ICSI
Drospirenone drug, Cetrorelix 0.25 mg - Poor Ovarian Reserve, Infertility (IVF Patients)
Phase 1 / Phase 2Not yet recruitingAhmed Saad1002026-08-012026-07-30
Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS?!
Cetrorelix drug, Drospirenone drug - PCOS (Polycystic Ovary Syndrome)
Phase 1 / Phase 2CompletedAhmed Saad502024-10-012025-01-22
Progesterone Primed Protocol Versus GnRH Antagonist in With PCO Undergoing ICSI
Dydrogesterone Tablets, Cetrorelix - IVF, PCO
Phase 2 / Phase 3CompletedBeni-Suef University2002024-01-012026-04-15
Efficacy and Safety of BG2109 During Controlled Ovarian Hyperstimulation in Female Subjects Undergoing ART Procedures
BG2109, Cetrorelix - Assisted Reproductive Technology, Controlled Ovarian Hyperstimulation
Phase 2UnknownBio Genuine (Shanghai) Biotech Co., Ltd.2402023-08-012023-07-27
Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
Human Chorionic Gonadotropin (hCG), Gonadotropins, GNRH-A Triptorelin - Female Infertility, Female Infertility Due to Ovulatory Disorder
Phase 1 / Phase 2CompletedLebanese University2002018-02-012023-05-09
Antagonist Protocol in IVF
Gonadotropins releasing hormone antagonist - Infertility
Phase 2UnknownWoman's Health University Hospital, Egypt2002015-01-012016-02-15
Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome
Cetrorelix - Infertility
Phase 2 / Phase 3UnknownBenha University482014-10-012017-03-30
Gonadotropin Releasing Hormone Antagonist in Treatment of Early-onset Severe Ovarian Hyperstimulation Syndrome
Cetrorelix - Assisted Reproduction
Phase 2CompletedAin Shams University842014-06-012016-05-27
Gonadotropin-Releasing Hormone (GnRH)-Antagonist Therapy in Rheumatoid Arthritis
Cetrorelix, Placebo - Rheumatoid Arthritis
Phase 2CompletedBetanien Hospital1042008-05-012012-08-06
A Phase II Study to Assess the Efficacy and Safety of LuverisĀ® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age
r-hLH + r-hFSH, r-hFSH, Recombinant Human Choriogonadotropin (r-hCG) - Infertility, Ovulation Induction
Phase 2TerminatedMerck KGaA, Darmstadt, Germany932007-11-012014-02-27
Lutropin Alfa in Women at Risk of Poor Response
r-FSH, r-hLH, Analogous GnRH antagonist - Ovarian Stimulation
Phase 2CompletedMerck KGaA, Darmstadt, Germany582005-12-072018-08-28
A Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy, Safety and Duration of Effect of a Single Administration of Various Doses of Cetrorelix SR in Subjects With Histologically Confirmed Endometriosis
Cetrorelix - Endometriosis
Phase 2CompletedSolvay Pharmaceuticals2005-11-012008-03-31
Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS)
Cetrotide - Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS)
Phase 1 / Phase 2WithdrawnWolfson Medical Center2016-03-30

Conditions studied

Infertility (5)  ·  Endometriosis (2)  ·  Helping Behavior (2)  ·  Polycystic Ovary Syndrome (2)  ·  Arthritis, Rheumatoid (1)  ·  Endometritis (1)  ·  Infertility, Female (1)  ·  Leiomyoma (1)  ·  Pregnancy, Ectopic (1)  ·  Primary Ovarian Insufficiency (1)  ·  Salpingitis (1)  ·  Uterine Anomalies (1)

Sponsors

Ahmed Saad (2)  ·  Merck KGaA, Darmstadt, Germany (2)  ·  Ain Shams University (1)  ·  Benha University (1)  ·  Beni-Suef University (1)  ·  Betanien Hospital (1)  ·  Bio Genuine (Shanghai) Biotech Co., Ltd. (1)  ·  Lebanese University (1)  ·  Solvay Pharmaceuticals (1)  ·  Wolfson Medical Center (1)  ·  Woman's Health University Hospital, Egypt (1)

Countries

Egypt (5)  ·  Spain (2)  ·  Australia (1)  ·  Belgium (1)  ·  Bulgaria (1)  ·  China (1)  ·  Germany (1)  ·  Lebanon (1)  ·  Norway (1)  ·  Romania (1)  ·  Russia (1)  ·  South Africa (1)  ·  Ukraine (1)

Top investigators

Dina M Dakhly, MD (1)  ·  Nehman Makdissy, Professor (1)  ·  Samar El Hamoui, Dr (1)  ·  Xiaoyan Liang (1)

Results publications

PMID 26460564, PMID 29132339

NIH funding

2004 (1), 2005 (1)